Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
72.13 USD | -1.35% | +0.18% | +0.71% |
Financials (USD)
Sales 2024 * | 662M | Sales 2025 * | 923M | Capitalization | 7.67B |
---|---|---|---|---|---|
Net income 2024 * | -59M | Net income 2025 * | 108M | EV / Sales 2024 * | 10.5 x |
Net cash position 2024 * | 755M | Net cash position 2025 * | 839M | EV / Sales 2025 * | 7.41 x |
P/E ratio 2024 * |
-115
x | P/E ratio 2025 * |
63.6
x | Employees | 610 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.58% |
Latest transcript on Intra-Cellular Therapies, Inc.
1 day | -1.35% | ||
1 week | +0.18% | ||
Current month | +4.23% | ||
1 month | +6.12% | ||
3 months | +7.69% | ||
6 months | +49.03% | ||
Current year | +0.71% |
Managers | Title | Age | Since |
---|---|---|---|
Sharon Mates
CEO | Chief Executive Officer | 71 | 13-08-28 |
Director of Finance/CFO | 67 | 13-08-28 | |
Michael Halstead
PSD | President | 51 | 14-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Rory Riggs
BRD | Director/Board Member | 71 | 14-01-07 |
Joel Marcus
BRD | Director/Board Member | 76 | 13-08-28 |
Director/Board Member | 67 | 14-01-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.14% | 16 M€ | -8.49% | ||
0.45% | 0 M€ | 0.00% | - | |
0.40% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 72.13 | -1.35% | 658,777 |
24-04-24 | 73.12 | -1.20% | 736,512 |
24-04-23 | 74.01 | -0.71% | 826,601 |
24-04-22 | 74.54 | +3.00% | 1,927,853 |
24-04-19 | 72.37 | +0.51% | 2,189,254 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.71% | 7.67B | |
-4.66% | 87.53B | |
+2.63% | 40.42B | |
-21.76% | 29.48B | |
+56.59% | 25.43B | |
-14.78% | 15.59B | |
-18.49% | 11.49B | |
-15.61% | 11.1B | |
-44.02% | 11.3B | |
+5.17% | 8.75B |
- Stock Market
- Equities
- ITCI Stock